Neuraceq Injection, Solution
Product Images NDC 54828-001

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Neuraceq (NDC 54828-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lantheus Biosciences Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure (Figure)

Figure (Figure)
The text describes different regions of the brain: Cerebellum, Lateral temporal, Frontal lobes, Posterior cingulate/Parietal lobes, and Precuneus. It also mentions "Neuraceq" and two possible scan results: "Negative Scan" and "Positive Scan". Neuraceq is likely a medical imaging agent used for positron emission tomography (PET) scans to visualize beta-amyloid plaques in the brain, which are associated with Alzheimer's disease.*
FDA Label Image

Shield Label Nm 06 2022 Fda Approved Lmi

Shield Label Nm 06 2022 Fda Approved Lmi
This text provides information about a medical product called Neuraceq®. It is a sterile non-pyrogenic injection used for diagnostic purposes, meant for intravenous use only. Each ml of the injection contains up to 3 meg of lrbetaben and 50 MBa/mL to 5,000 MBymL, along with other components such as ascorbic acid and sodium ascorbate. It is recommended to dispense the injection aseptically and store it at room temperature or within 2 to 42°C (36°F to 108°F). The text includes details on dosage and storage instructions, as well as batch number and expiration date.*
FDA Label Image

Shield Label Sofie 06 2022 Fda Approved Lmi

Shield Label Sofie 06 2022 Fda Approved Lmi
This is a description of Neuraceq, a sterile non-pyrogenic injectable radioactive drug used for intravenous diagnosis. It comes in a 50 mL multiple-dose vial and contains up to 3 meg of arbefaben and 50 MBa to 5,000 MBymL with other additives. The recommended dose is specified in the prescribing information. It should be dispensed into a sterile syringe or container within a lead shielded secondary container. It should be stored upright in its original container or its radiation shielding equivalent. The storage temperature should be maintained at 5°C with excursions permitted to 2°C to 42°C. It is not recommended to use the drug if it contains cloudy or particulate matter. The drug can only be used by RxONLY, and it has a batch number and expiration date/time.*
FDA Label Image

Structure (Structure)

Structure (Structure)
FDA Label Image

Vial Label Nm 06 2022 Fda Approved Lmi

Vial Label Nm 06 2022 Fda Approved Lmi
This is a description of a medication called Newacea SterleNon-rogenc Darheiaben. It is intended for intravenous use only and comes in a 50mL vial. Each vial contains 3g of Sotetlan and additional ingredients such as ascorbic acid and sodium ascorbate. The medication should be stored at temperatures between 2°C to 42°C. It is important to store it in a radiation shielding container and not use it if it appears cloudy or contains particulate matter.*
FDA Label Image

Vial Label Sofie 06 2022 Fda Approved Lmi

Vial Label Sofie 06 2022 Fda Approved Lmi
This is a description of a diagnostic injection for intravenous use only. It comes in a 50 mL multiple-dose vial with a shelf life of 10 months after the expiration date mentioned. The injection contains up to 3 grams of Sotetlia, 44 mg of Ascorbic Acid, and 118 mg of stanel among other ingredients. The injection must be stored upright between 2°C to 42°C and away from cloudy or particulate matter.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.